Literature DB >> 24093638

Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies.

Kelley L Colvin1, Patrick J Cripe, D Dunbar Ivy, Kurt R Stenmark, Michael E Yeager.   

Abstract

RATIONALE: Autoimmunity has long been associated with pulmonary hypertension. Bronchus-associated lymphoid tissue plays important roles in antigen sampling and self-tolerance during infection and inflammation.
OBJECTIVES: We reasoned that activated bronchus-associated lymphoid tissue would be evident in rats with pulmonary hypertension, and that loss of self-tolerance would result in production of pathologic autoantibodies that drive vascular remodeling.
METHODS: We used animal models, histology, and gene expression assays to evaluate the role of bronchus-associated lymphoid tissue in pulmonary hypertension.
MEASUREMENTS AND MAIN RESULTS: Bronchus-associated lymphoid tissue was more numerous, larger, and more active in pulmonary hypertension compared with control animals. We found dendritic cells in and around lymphoid tissue, which were composed of CD3(+) T cells over a core of CD45RA(+) B cells. Antirat IgG and plasma from rats with pulmonary hypertension decorated B cells in lymphoid tissue, resistance vessels, and adventitia of large vessels. Lymphoid tissue in diseased rats was vascularized by aquaporin-1(+) high endothelial venules and vascular cell adhesion molecule-positive vessels. Autoantibodies are produced in bronchus-associated lymphoid tissue and, when bound to pulmonary adventitial fibroblasts, change their phenotype to one that may promote inflammation. Passive transfer of autoantibodies into rats caused pulmonary vascular remodeling and pulmonary hypertension. Diminution of lymphoid tissue reversed pulmonary hypertension, whereas immunologic blockade of CCR7 worsened pulmonary hypertension and hastened its onset.
CONCLUSIONS: Bronchus-associated lymphoid tissue expands in pulmonary hypertension and is autoimmunologically active. Loss of self-tolerance contributes to pulmonary vascular remodeling and pulmonary hypertension. Lymphoid tissue-directed therapies may be beneficial in treating pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24093638      PMCID: PMC3863738          DOI: 10.1164/rccm.201302-0403OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  32 in total

1.  Acute lung injury: apoptosis in effector and target cells of the upper and lower airway compartment.

Authors:  B Roth Z'graggen; J Tornic; B Müller-Edenborn; L Reyes; C Booy; B Beck-Schimmer
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Regulation of inducible BALT formation and contribution to immunity and pathology.

Authors:  S Y Foo; S Phipps
Journal:  Mucosal Immunol       Date:  2010-09-01       Impact factor: 7.313

Review 3.  Development and pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; Steven H Abman; Thomas Braun; Frédérique Capron; Troy Stevens; Patricia A Thistlethwaite; Sheila G Haworth
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

4.  Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link?

Authors:  D B Badesch; K M Wynne; S Bonvallet; N F Voelkel; C Ridgway; B M Groves
Journal:  Ann Intern Med       Date:  1993-07-01       Impact factor: 25.391

5.  Activation-induced cytidine deaminase induces reproducible DNA breaks at many non-Ig Loci in activated B cells.

Authors:  Ori Staszewski; Richard E Baker; Anna J Ucher; Raygene Martier; Janet Stavnezer; Jeroen E J Guikema
Journal:  Mol Cell       Date:  2011-01-21       Impact factor: 17.970

6.  Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans.

Authors:  Huijuan Lv; Evis Havari; Sheena Pinto; Raju V S R K Gottumukkala; Lizbeth Cornivelli; Khadir Raddassi; Takashi Matsui; Anthony Rosenzweig; Roderick T Bronson; Ross Smith; Anne L Fletcher; Shannon J Turley; Kai Wucherpfennig; Bruno Kyewski; Myra A Lipes
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

7.  Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung.

Authors:  Nakaaki Kawamata; Baohui Xu; Hiroo Nishijima; Kohji Aoyama; Mayumi Kusumoto; Toru Takeuchi; Chuwa Tei; Sara A Michie; Takami Matsuyama
Journal:  Respir Res       Date:  2009-10-22

8.  Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung.

Authors:  Sho Goya; Hiroto Matsuoka; Masahide Mori; Hiroshi Morishita; Hiroshi Kida; Yoichiro Kobashi; Terufumi Kato; Yoshio Taguchi; Tadashi Osaki; Isao Tachibana; Norihiro Nishimoto; Kazuyuki Yoshizaki; Ichiro Kawase; Seiji Hayashi
Journal:  J Pathol       Date:  2003-05       Impact factor: 7.996

Review 9.  Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

Authors:  Kurt R Stenmark; Barbara Meyrick; Nazzareno Galie; Wolter J Mooi; Ivan F McMurtry
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-09-11       Impact factor: 5.464

Review 10.  Bronchus-associated lymphoid tissue (BALT) structure and function.

Authors:  Troy D Randall
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

View more
  32 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  C-C Motif Chemokine Receptor 7 Exacerbates Hypertension Through Effects on T Lymphocyte Trafficking.

Authors:  Yi Wen; Nathan P Rudemiller; Jiandong Zhang; Xiaohan Lu; Jiafa Ren; Jamie R Privratsky; Robert Griffiths; Junyi J Zhang; Gianna E Hammer; Steven D Crowley
Journal:  Hypertension       Date:  2020-01-27       Impact factor: 10.190

3.  Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension.

Authors:  Ayser Al-Husseini; Donatas Kraskauskas; Eleanora Mezzaroma; Andrea Nordio; Daniela Farkas; Jennifer I Drake; Antonio Abbate; Quentin Felty; Norbert F Voelkel
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 4.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch; Christophe Guignabert; Marc Humbert; Mark R Nicolls
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 5.  Update in pulmonary vascular diseases 2013.

Authors:  Paul M Hassoun; Paul T Schumacker
Journal:  Am J Respir Crit Care Med       Date:  2014-10-01       Impact factor: 21.405

Review 6.  Infections in the immunosuppressed host.

Authors:  M Patricia George; Henry Masur; Karen A Norris; Scott M Palmer; Cornelius J Clancy; John F McDyer
Journal:  Ann Am Thorac Soc       Date:  2014-08

7.  Safety and Efficacy of Immunoadsorption as an Add-On to Medical Treatment in Patients with Severe Idiopathic Pulmonary Arterial Hypertension.

Authors:  Christian Nagel; Ralf Ewert; Benjamin Egenlauf; Hans B Lehmkuhl; Stephan Rosenkranz; Nicola Benjamin; Vedat Schwenger; Felix J F Herth; Ekkehard Grünig
Journal:  Respiration       Date:  2017-08-05       Impact factor: 3.580

Review 8.  A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.

Authors:  Wolfgang M Kuebler; Mark R Nicolls; Andrea Olschewski; Kohtaro Abe; Marlene Rabinovitch; Duncan Stewart; Stephen Y Chan; Nicholas W Morrell; Stephen L Archer; Edda Spiekerkoetter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-07       Impact factor: 5.464

Review 9.  Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?

Authors:  Thenappan Thenappan; Alexander Khoruts; Yingjie Chen; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-09-06       Impact factor: 4.733

Review 10.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.